1,285 enforcement actions from 14 federal and state jurisdictions. Every event traced back to its official government source.
1,285
Total Actions
14
Jurisdictions
$35.3B+
Total Fines Tracked
Connecticut Attorney General William Tong led a coalition of 48 states and territories in announcing settlements with Lannett Company, Inc. and Bausch Health entities totaling $17.85 million. The settlements resolve allegations that the companies engaged in conspiracies to inflate prices and limit competition for generic prescription drugs. The companies agreed to cooperate in ongoing litigation and implement internal reforms, while a new complaint was filed against Novartis and subsidiaries.
$17.9M
The U.S. Bankruptcy Court confirmed a $7.4 billion settlement between Purdue Pharma, the Sackler Family, and 55 attorneys general to resolve claims over the opioid crisis. Connecticut will receive up to $64 million for treatment, prevention, and victim support. The settlement bars the Sacklers from selling opioids and requires public disclosure of documents.
$7.4B
Connecticut Attorney General William Tong leads a multistate coalition in a $39.1 million settlement with Apotex for conspiracy to inflate generic drug prices and limit competition. The settlement resolves allegations of widespread price-fixing and requires Apotex to pay compensation to affected consumers, agree to injunctive relief, and implement internal reforms to ensure antitrust compliance.
$39.1M
Attorney General William Tong announced settlements with Heritage Pharmaceuticals and Apotex totaling $49.1 million to resolve allegations of price-fixing conspiracies for generic prescription drugs. The companies agreed to cooperate in ongoing multistate litigation and implement internal reforms to ensure fair competition.
$49.1M
State attorneys general reached a $450 million settlement with opioid manufacturer Endo International plc as part of its bankruptcy. The settlement resolves allegations of deceptive marketing that downplayed addiction risks and overstated benefits, particularly for Opana ER. Endo must pay $450 million over 10 years, ban opioid marketing forever, and disclose millions of documents.
$450.0M
All data sourced from official government enforcement pages.